ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för tofacitinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

25 träffar

Bibliografisk träff 2012-11-01

JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.

LaBranche TP, Jesson MI, Radi ZA, Storer CE, Guzova JA, Bonar SL, Thompson JM, Happa FA, Stewart ZS, Zhan Y, Bollinger CS, Bansal PN, Wellen JW, Wilkie DP, Bailey SA, Symanowicz PT, Hegen M, Head RD, Kishore N, Mbalaviele G, Meyer DM.

Arthritis Rheum · research support, non-u.s. gov't; journal article · DOI 10.1002/art.34649

Bibliografisk träff 2012-11-01

Tofacitinib in active ulcerative colitis.

Paul S, Roblin X.

N Engl J Med · letter; comment · DOI 10.1056/nejmc1211073

Bibliografisk träff 2012-11-01

Tofacitinib in active ulcerative colitis.

Cottone M, Orlando A, Papi C.

N Engl J Med · letter; comment · DOI 10.1056/nejmc1211073

Bibliografisk träff 2012-09-21

Kinase inhibitors: a new class of antirheumatic drugs.

Kyttaris VC.

Drug Des Devel Ther · review-article; review; journal article; research support, n.i.h., extramural · DOI 10.2147/dddt.s25426

Bibliografisk träff 2012-09-01

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, Gupta P, Krishnaswami S, Tan H, Harness JA.

Br J Dermatol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1365-2133.2012.11168.x

Bibliografisk träff 2012-09-01

Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.

Vafadari R, Quaedackers ME, Kho MM, Mol WM, Chan G, Weimar W, Baan CC.

Transplantation · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1097/tp.0b013e3182626b5a

Bibliografisk träff 2012-08-01

[Janus kinase inhibitors].

Ostermeier E, Roll P, Tony HP.

Z Rheumatol · journal article; english abstract · DOI 10.1007/s00393-011-0879-2

Bibliografisk träff 2012-08-01

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.

Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS, ORAL Solo Investigators.

N Engl J Med · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa1109071

Bibliografisk träff 2012-08-01

Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B, ORAL Standard Investigators.

N Engl J Med · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa1112072

Bibliografisk träff 2012-08-01

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W, Study A3921063 Investigators.

N Engl J Med · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa1112168

Bibliografisk träff 2012-08-01

Tofacitinib for the treatment of moderate to severe rheumatoid arthritis.

de Lartigue J.

Drugs Today (Barc) · journal article · DOI 10.1358/dot.2012.48.8.1855926

Bibliografisk träff 2012-07-01

Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.

Gupta P, Alvey C, Wang R, Dowty ME, Fahmi OA, Walsky RL, Riese RJ, Krishnaswami S.

Br J Clin Pharmacol · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1111/j.1365-2125.2012.04168.x

Bibliografisk träff 2012-06-11

Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.

Kulagowski JJ, Blair W, Bull RJ, Chang C, Deshmukh G, Dyke HJ, Eigenbrot C, Ghilardi N, Gibbons P, Harrison TK, Hewitt PR, Liimatta M, Hurley CA, Johnson A, Johnson T, Kenny JR, Bir Kohli P, Maxey RJ, Mendonca R, Mortara K, Murray J, Narukulla R, Shia S, Steffek M, Ubhayakar S, Ultsch M, van Abbema A, Ward SI, Waszkowycz B, Zak M.

J Med Chem · journal article · DOI 10.1021/jm300438j

Bibliografisk träff 2012-06-08

Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.

Vincenti F, Tedesco Silva H, Busque S, O'Connell P, Friedewald J, Cibrik D, Budde K, Yoshida A, Cohney S, Weimar W, Kim YS, Lawendy N, Lan SP, Kudlacz E, Krishnaswami S, Chan G.

Am J Transplant · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1600-6143.2012.04127.x

Bibliografisk träff 2012-05-18

Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.

Huang JF, Yafawi R, Zhang M, McDowell M, Rittenhouse KD, Sace F, Liew SH, Cooper SR, Pickering EH.

Ophthalmology · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; multicenter study; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1016/j.ophtha.2012.03.017

Bibliografisk träff 2012-05-01

Novel small-molecular therapeutics for rheumatoid arthritis.

Fleischmann R.

Curr Opin Rheumatol · review; journal article · DOI 10.1097/bor.0b013e32835190ef

Bibliografisk träff 2012-05-01

Tofacitinib for the treatment of rheumatoid arthritis.

Zerbini CA, Lomonte AB.

Expert Rev Clin Immunol · review; journal article · DOI 10.1586/eci.12.19

Bibliografisk träff 2012-04-22

Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.

Liew SH, Nichols KK, Klamerus KJ, Li JZ, Zhang M, Foulks GN.

Ophthalmology · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; multicenter study; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1016/j.ophtha.2012.01.028

Bibliografisk träff 2012-04-03

Risk of tuberculosis reactivation with tofacitinib (CP-690550).

Maiga M, Lun S, Guo H, Winglee K, Ammerman NC, Bishai WR.

J Infect Dis · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1093/infdis/jis269

Bibliografisk träff 2012-04-01

In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.

Tanaka Y, Maeshima K, Yamaoka K.

Ann Rheum Dis · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1136/annrheumdis-2011-200595

Bibliografisk träff 2012-03-01

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.

Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, Connell CA, Gruben D, Krishnaswami S, Wallenstein G, Wilkinson BE, Zwillich SH.

Arthritis Rheum · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1002/art.33383

Bibliografisk träff 2012-01-01

[Anti-rheumatic effect of JAK-inhibitors].

Yamaoka K, Maeshima K, Kubo S, Sonomoto K, Tanaka Y.

Nihon Rinsho Meneki Gakkai Kaishi · journal article; english abstract · DOI 10.2177/jsci.35.112

Bibliografisk träff 2011-12-06

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.

Maeshima K, Yamaoka K, Kubo S, Nakano K, Iwata S, Saito K, Ohishi M, Miyahara H, Tanaka S, Ishii K, Yoshimatsu H, Tanaka Y.

Arthritis Rheum · research support, non-u.s. gov't; journal article · DOI 10.1002/art.34329

Bibliografisk träff 2011-12-01

Targeting JAK3 in kidney transplantation: current status and future options.

Wojciechowski D, Vincenti F.

Curr Opin Organ Transplant · review; journal article · DOI 10.1097/mot.0b013e32834c23ce

Bibliografisk träff 2011-10-17

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.

Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH.

Arthritis Rheum · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1002/art.33419